Home/Filings/4/0001140361-17-029590
4//SEC Filing

Beddingfield III Frederick 4

Accession 0001140361-17-029590

CIK 0001656328other

Filed

Jul 31, 8:00 PM ET

Accepted

Aug 1, 4:20 PM ET

Size

16.0 KB

Accession

0001140361-17-029590

Insider Transaction Report

Form 4
Period: 2017-08-01
Beddingfield III Frederick
DirectorPresident & CEO
Transactions
  • Conversion

    Series A-3 Preferred Stock

    2017-08-0114,0760 total(indirect: See Footnote)
    Common Stock (14,076 underlying)
  • Conversion

    Series A-3 Preferred Stock

    2017-08-01112,6140 total(indirect: See Footnote)
    Common Stock (112,614 underlying)
  • Conversion

    Common Stock

    2017-08-01+14,07614,076 total(indirect: See Footnote)
  • Conversion

    Series A-3 Preferred Stock

    2017-08-0114,0760 total(indirect: See Footnote)
    Common Stock (14,076 underlying)
  • Conversion

    Common Stock

    2017-08-01+14,07614,076 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2017-08-01+112,614112,614 total(indirect: See Footnote)
Holdings
  • Common Stock

    553,652
Footnotes (5)
  • [F1]The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
  • [F2]The shares are directly held by Beddingfield Children's Trust fbo Catherine Sara Beddingfield.
  • [F3]The shares are directly held by Beddingfield Children's Trust fbo Claire Elizabeth Beddingfield.
  • [F4]The shares are directly held by the Beddingfield Family Trust.
  • [F5]The expiration date is not relevant to the conversion of these securities.

Documents

1 file

Issuer

Sienna Biopharmaceuticals, Inc.

CIK 0001656328

Entity typeother

Related Parties

1
  • filerCIK 0001573074

Filing Metadata

Form type
4
Filed
Jul 31, 8:00 PM ET
Accepted
Aug 1, 4:20 PM ET
Size
16.0 KB